MACOPB方案治疗复发或难治性非霍奇金淋巴瘤的临床分析  

Clinical study on effect of MACOPB protocol in treatment of refractory or relapsed non-Hodgkin's lymphoma

作　　者：曹俊杰[1] 裴仁治[1] 马俊霞[1] 张丕胜[1] 刘旭辉[1] 杜小红[1] 陈冬[1] 沙科娅[1] 陈列光[1] 李双月[1] 吴静怡[1] 林丽[1] 范峥[1] 叶佩佩[1] 张碧波[1] 唐善浩[1] 史晓薇[1] 

机构地区：[1]宁波大学附属鄞州医院血液科,浙江宁波315040

出　　处：《中国现代医生》2012年第33期120-121,共2页China Modern Doctor

基　　金：浙江省宁波市科技计划项目(2007C10084)

摘　　要：目的观察MACOPB方案治疗复发或难治性非霍奇金淋巴瘤(NHL)的近期疗效及不良反应。方法对28例难治复发性NHL患者应用MACOPB方案(MTX 400 mg/m2第2、6、10周静滴,24 h后四氢叶酸钙15 mg/m2,qh×6次解救,MIT 6 mg/m2第1、3、5、7、9、11周静滴,CTX 400 mg/m2第1、3、5、7、9、11周静滴,VCR 2 mg第2、4、6、8、10、12周静滴,DXM 10 mg qd×2周静滴后减量,BLM 10mg/m2第4、8、12周静滴)化疗,评定疗效。结果 28例患者总有效率为78.6%(22/28),完全缓解(CR)率为60.7%(17/28),部分缓解(PR)率为17.9%(5/28)。毒副反应主要为骨髓抑制、黏膜炎、胃肠道反应等。全组病例支持治疗下均能完成所有化疗,全组无致死性毒性反应发生。结论 MACOPB方案可用于治疗难治复发性NHL,有较好的近期疗效,治疗相关不良反应轻微,易于控制。为能够再次缓解的复发淋巴瘤患者进行造血干细胞移植提供了治疗机会。Objective To investigate the short efficacy and side effects of MACOPB protocol in treatment of the patients with refractory or relapsed non-Hodgkin＇s lymphoma. Methods A total of 28 patients with refractory or relapsed non- Hodgkin＇s lymphoma received MACOPB protocol （cyclophosphamide 400 mg/m^2 and mitoxantrone 6 mg/m^2 given i.v. on weeks 1, 3, 5, 7, 9 and 11; methotrexate 400 mg/m^2 on weeks 2,6 and 10 followed by leucovorin rescue; vincristine 1.4 mg/m^2 on weeks 2, 4, 6, 8, 10 and 12;bleomycin 10 mg/m^2 on weeks 4, 8 and 12 and dexamethasone 10 mg for 2 weeks）. Results Of all the 28 patients,the overall response rate was78.6% （22/28）,the complete response rate was60.7% （17/28）, the partial response rate was17.9% （5/28）. The main sideeffects were bone marrow suppression, mucositis and gastrointestinal tract reactions. Conclusion MACOPB protocol chemotherapy had a better short efficacy for refractory or relapsed non- Hodgkin＇s lymphoma and minor sideeffects,which makes a chance for hematopoietic stem cell transplantation.

关 键 词：MACOPB方案 复发 难治 非霍奇金淋巴瘤 

分 类 号：R733.1[医药卫生—肿瘤]